San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Erasca is raising $200 Million in new funding. Sources indicate as part of senior management President, Jonathan Lim played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Erasca

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

To learn more about Erasca, visit http://www.erasca.com/

Contact:
Jonathan Lim, President
858-465-6511
https://www.linkedin.com/in/jonathan-lim-m-d-317b3/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved